| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10947183 | UCB INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9603815 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US9549909 | UCB INC | Method for the treatment of dravet syndrome |
May, 2033
(9 years from now) | |
| US9610260 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
| US9603814 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US10478442 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
| US10478441 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
|
US10478441 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9549909 (Pediatric) | UCB INC | Method for the treatment of dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US10478442 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US9610260 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US9603814 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9603815 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
| US10950331 | UCB INC | Control system for control of distribution of medication |
Sep, 2035
(11 years from now) | |
|
US10950331 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Mar, 2036
(11 years from now) | |
|
US10947183 (Pediatric) | UCB INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(13 years from now) | |
| US11406606 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11759440 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11040018 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11786487 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US10603290 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
|
US11040018 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11786487 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11759440 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11406606 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US10603290 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
| US10452815 | UCB INC | Control system for control of distribution of medication |
Jun, 2038
(14 years from now) | |
|
US10452815 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Dec, 2038
(14 years from now) | |
Fintepla is owned by Ucb Inc.
Fintepla contains Fenfluramine Hydrochloride.
Fintepla has a total of 28 drug patents out of which 0 drug patents have expired.
Fintepla was authorised for market use on 25 June, 2020.
Fintepla is available in solution;oral dosage forms.
Fintepla can be used as method of reducing or ameliorating seizures in a patient by administering a liquid formulation of fenfluramine with stiripentol thereby modulating down the formation of norfenfluramine and resulting in higher levels of fenfluramine, use in combination with stiripentol for the treatment of seizures associated with dravet syndrome, use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with lennox gastaut syndrome, treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution, use in combination with cannabidiol for the treatment of seizures associated with lennox-gastaut syndrome, use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome, use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome, method of treating seizures in a patient by administering a liquid formulation of fenfluramine or its salts plus stiripentol thereby reducing norfenfluramine formation while increasing the fenfluramine level. patients can have e.g. dravet or lgs.
The generics of Fintepla are possible to be released after 29 December, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| New Product(NP) | Jun 25, 2023 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated...
Dosage: SOLUTION;ORAL
FINTEPLA family patents
